Navigation Links
Cystic fibrosis patients of low SES are less likely to be accepted for lung transplant
Date:9/13/2012

Adult cystic fibrosis (CF) patients of low socioeconomic status (SES) have a greater chance of not being accepted for lung transplant after undergoing initial evaluation, according to a new study.

"While earlier studies have indicated that SES does not affect access to care for cystic fibrosis, ours is the first study to examine the relationship between SES and access to lung transplantation in these patients," said lead author Bradley S. Quon, MD, MSc, MBA, of the University of Washington Medical Center in Seattle. "In our nationally representative sample of adult patients with CF, we found that multiple indicators of SES were associated with greater odds of not being accepted for transplant."

The findings were published online ahead of print publication in the American Thoracic Society's American Journal of Respiratory and Critical Care Medicine.

The study included 2,167 adult CF patients from the CF Foundation Patient registry, all of whom underwent their first lung transplant evaluation as an adult between January 1, 2001, and December 31, 2009. Receipt of Medicaid insurance was used as the primary indicator of SES status. The outcome of interest was acceptance onto the waiting list for lung transplant after initial evaluation. Patients who were either declined or deferred were classified as not accepted, and an additional sensitivity analysis was performed based on the final decision of whether a patient was accepted or declined at the end of the study period.

Of the 2,167 patients included in the study, 1009 (47%) received Medicaid. Compared to non-Medicaid patients, the odds of not being accepted for lung transplant was 1.56 fold higher among Medicaid recipients. This relationship was independent of differences in disease severity, demographic factors, contraindications to lung transplant, and use of the lung allocation score.

Other indicators of low SES, including residing in lower income zip codes and not graduating from high school, were also independently associated with not being accepted for lung transplant after undergoing initial evaluation.

The study had a few limitations, including the use of Medicaid and other indicators as proxies for SES status. Furthermore, inadequate social support and poor adherence are key determinants of transplant eligibility. Although the authors attempted to account for these factors in their analysis, incomplete adjustment for these variables may at least partially explain why low SES was associated with not being accepted for lung transplant.

"The results of our study are concerning, as the effects of SES status on access to lung transplant appear to be unrelated to differences in disease severity or potential contraindications," said Dr. Quon. "More research is needed to explore the factors associated with Medicaid status that negatively impact lung transplant access and to assess whether these disparities are seen in other pre-lung transplant patient populations."


'/>"/>
Contact: Nathaniel Dunford
ndunford@thoracic.org
212-315-8620
American Thoracic Society
Source:Eurekalert

Related medicine news :

1. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
2. Study evaluates use of inhaled saline for young children with cystic fibrosis
3. New drug successfully halts fibrosis in animal model of liver disease
4. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
5. Perceived control affects complication rates in patients with acute coronary syndrome
6. Physicians suggest expert recommendations ignore vital issues for patients
7. Docs Sensitivity to Patients Feelings Tied to Good Outcomes
8. Technique using CT linked with improved detection of lymph node metastasis in patients with melanoma
9. Tight blood sugar control for pediatric cardiac surgery patients does not improve outcomes
10. No proof that patients lose weight after joint replacement surgery
11. Language Barrier Hurts Elderly Asthma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... ... , ... CareSet Labs released the Root NPI Graph today at the 2017 ... improved version of the Doctor Referral teaming dataset commonly available from Medicare. , Originally ... the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released by ...
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the focus is ... among men in the U.S. and the third most common cause of cancer related death ... man in seven will be diagnosed with prostate cancer during his lifetime. Those at ...
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ Society’s ... and Erie Convention Center on June 8-10. The weekend consisted of many ... award and scholarship presentations, and professional networking. , On Friday June 9th, ...
(Date:6/24/2017)... , ... June 24, 2017 , ... The weather is ... time outdoors. Home and business owners should be aware that the summer months provide ... In fact, mechanical locks and keys can be negatively affected from direct exposure to ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... today announced the launch of Care Management Alerts and Dashboards, an innovative new ... throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide near real-time ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... Calif. , June 14, 2017 The ... the City of Fremont and ... of the bio-pharma industry in California ... technology, enabling executive networking, and fostering workforce development. The ... development and growth of start-ups, as well as small ...
(Date:6/13/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... Food and Drug Administration (FDA) has notified the Company that ... Zhejiang, China manufacturing facility has been ... clearance of the Warning Letter related to our ... of the progress we have made in our ongoing quality ...
(Date:6/11/2017)... and Company (NYSE: LLY ) announced today ... an investigational treatment for the prevention of episodic and ... endpoints for galcanezumab compared to placebo at both studied ... REGAIN) will be presented today at the American Headache ... . "The detailed Phase 3 ...
Breaking Medicine Technology: